Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 1997

View Archived Issues

Company Profile: Sepracor

EntreMed reports positive preclinical results using Endostatin

Maillard reaction inhibitors from Kissei

Takeda discloses new series of prolactin secretion inhibitors

Antiangina agents in development at Sankyo

Water-soluble taxanes reported in patent literature

Preclinical profile of Co-102862 presented at neuroscience congress

Behavioral effects of neurosteroid elucidated in nonhuman primate model

Anticonvulsant activity demonstrated for adenosine kinase inhibitor

Cypress Bioscience: Q3 1997 highlights

Combination malaria vaccine enters phase I

FDA approves ANDA for generic clozapine

Reduced PSF expression associated with development of vascular lesions

HCV protease inhibitors to be designed and developed by BMS and Arris

Compounds for 5-HT-mediated disorders from Astra

CoCensys/Acea reveal new AMPA receptor antagonists/positive modulators

VEGF receptor tyrosine kinase inhibitors under development at Zeneca

Neurogen patents new dopamine receptor subtype-specific ligands

Mechanism of renoprotective effects of ACE inhibitors in diabetic nephropathy

Kissei accelerates overseas development

ID Vaccine acquires rights to new AIDS vaccine

Yamanouchi advances overseas development

Valsartan approved in Canada

Intermittent therapy with 5-HT reuptake inhibitor effective for dysphoric PMS

Pfizer discontinues collaboration with Megabios

Amarillo reports positive phase II data in Sjogren's syndrome trial

Novo Nordisk licenses tiagabine to Sanofi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026